These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34062302)

  • 1. HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.
    Michel A; Oppong MD; Rauschenbach L; Pierscianek D; Dinger TF; Schmidt T; Hense J; Pöttgen C; Kimmig R; Ahmadipour Y; Özkan N; Müller O; Junker A; Sure U; Jabbarli R; El Hindy N
    World Neurosurg; 2021 Aug; 152():e332-e343. PubMed ID: 34062302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.
    Duchnowska R; Dziadziuszko R; Trojanowski T; Mandat T; Och W; Czartoryska-Arłukowicz B; Radecka B; Olszewski W; Szubstarski F; Kozłowski W; Jarosz B; Rogowski W; Kowalczyk A; Limon J; Biernat W; Jassem J;
    Breast Cancer Res; 2012 Aug; 14(4):R119. PubMed ID: 22898337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
    Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
    Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
    Melisko ME; Moore DH; Sneed PK; De Franco J; Rugo HS
    J Neurooncol; 2008 Jul; 88(3):359-65. PubMed ID: 18398574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of triple negative phenotype on breast cancer prognosis.
    Kaplan HG; Malmgren JA
    Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
    Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
    Chen R; Qarmali M; Siegal GP; Wei S
    Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
    Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
    Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
    Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
    Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
    Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between HER2 Proto-oncogene Status and Prognostic Factors of Breast Cancer in the West of Iran.
    Amirifard N; Sadeghi E; Payandeh M; Mohebbi H; Sadeghi M; Choubsaz M
    Asian Pac J Cancer Prev; 2016; 17(1):295-8. PubMed ID: 26838227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.